PharmTech

EMA and FDA Collaborate on Framework for AI Use in Drug Development

FDA and EMA have issued 10 guiding principles for AI in drug development with the intended goal of ensuring safety and ...

Allos Raises $5M to Apply Causal AI Across Complex Drug Reformulation

Allos AI today announced $5 million in seed financing led by Oxford Science Enterprises (OSE) to commercialize the industry's ...
The Pharma Letter

FDA and EMA guiding principles for good AI practice in drug development

After several months of collaboration, the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have ...
Forbes

Adoption Of Model-Informed Drug Development Can Improve Pharma ROI

Inflation and the Covid-19 pandemic have put pharmaceutical productivity front and center in recent years. Thus, drug companies are under mounting pressure to prove that new treatments are safe and ...
Hosted on MSN

SK Biopharma inks MOU with PhnyX Lab to creat AI-powered drug development framework

Yoo Chang-ho, head of strategy at SK Biopharmaceuticals, left, and Bae Min-seok, CEO of PhnyX Lab, pose for a commemorative photo marking the signing of a memorandum of understanding on AI-based drug ...
Medscape

Oncologic Drug Development Needs to Be Patient Centered

Oncologic drug development needs to place a greater focus on the patient, according to a commentary in the current issue of the New England Journal of Medicine. Even though the US Food and Drug ...
The American Journal of Managed Care

FDA Q&A: Addressing Biosimilar Safety, AI in Drug Development, and Supply Chain Challenges

In a Q&A, an FDA spokesperson discusses efforts to reduce misinformation about biosimilars through education, the agency’s collaboration with global regulators to streamline development, and its work ...